Jpmorgan Chase & CO Arca Biopharma, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$1.71 - $4.0 $3 - $8	-2 Reduced 11.11%	16 $0
Q1 2024 May 10, 2024	BUY	$1.58 - $1.78 $3 - $3	2 Added 12.5%	18 $0
Q4 2023 Feb 12, 2024	BUY	$1.7 - $2.05 $6 - $8	4 Added 33.33%	16 $0
Q3 2023 Nov 14, 2023	BUY	$2.01 - $2.07 $24 - $24	12 New	12 $0
Q2 2022 Aug 11, 2022	SELL	$2.2 - $2.53 $1,485 - $1,707	-675 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$1.77 - $2.49 $1,194 - $1,680	675 New	675 $2,000

280K

Ticker ABIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,410,100
Description
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.